Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Free Cash Flow (2016 - 2025)

iBio (IBIO) has disclosed Free Cash Flow for 16 consecutive years, with -$5.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 47.58% to -$5.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$19.2 million, a 17.46% decrease, with the full-year FY2025 number at -$15.3 million, up 18.38% from a year prior.
  • Free Cash Flow was -$5.8 million for Q4 2025 at iBio, down from -$5.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$3.1 million in Q1 2025 to a low of -$16.4 million in Q3 2022.
  • A 5-year average of -$7.2 million and a median of -$5.6 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 116.39% in 2021, then skyrocketed 67.51% in 2023.
  • iBio's Free Cash Flow stood at -$12.8 million in 2021, then grew by 17.4% to -$10.6 million in 2022, then skyrocketed by 55.56% to -$4.7 million in 2023, then rose by 17.11% to -$3.9 million in 2024, then crashed by 47.58% to -$5.8 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Free Cash Flow are -$5.8 million (Q4 2025), -$5.7 million (Q3 2025), and -$4.6 million (Q2 2025).